...
首页> 外文期刊>Acta Radiologica >Sequential combination treatment (arterial embolization and percutaneous radiofrequency ablation) of inoperable renal cell carcinoma: Single-center pilot study
【24h】

Sequential combination treatment (arterial embolization and percutaneous radiofrequency ablation) of inoperable renal cell carcinoma: Single-center pilot study

机译:不能手术的肾细胞癌的序贯联合治疗(动脉栓塞和经皮射频消融):单中心先导研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Potential drawbacks of percutaneous radiofrequency ablation (RFA) for renal cell carcinoma (RCC) include local recurrence after RFA due to a limited ablation area, massive hemorrhage induced by kidney puncture, and difficulty in visualizing the tumor at CT-guided puncture. Purpose: To evaluate retrospectively the technical success, effectiveness, and complications elicited in patients with unresectable RCC following single-session sequential combination treatment consisting of renal arterial embolization followed by RFA. Material and Methods: Ten patients (12 RCCs) who were not candidates for surgery were included in this pilot study. All tumors ranged from 18-66 mm in size (mean 31+3.9 mm), and were percutaneously ablated several hours after embolization of the tumor vessels with iodized oil and gelatin sponges. We evaluated the technical success, effectiveness, effect on renal function, and complications of this treatment. Effectiveness was judged on CT and/or MR images obtained every three months after RFA. The effect on renal function was assessed based on the creatinine level and glomerular filtration rate (GFR) before, one week, and three months after the procedure. Results: Renal arterial embolization followed by percutaneous RFAwas technically successful in all patients. On contrast CT and/or MR images obtained one week and three months after RFA we observed necrosis in the embolized segment of all RCCs. There were no major complications during and after the procedure. All patients reported tolerable pain and a burning sensation during RFA. After the procedure, five patients (50%) experienced back pain, one each manifested fluid collection, subcapsular hematomas, hematuria, or nausea. There were no instances of recurrence during a mean follow-up period of 47+3.8 months. We noted no significant difference in serum creatinine and GFR before and after treatment. Conclusion: Our pilot study suggests that sequential combination treatment by renal arterial embolization followed by percutaneous RFA is feasible in patients with inoperable RCC. The treatment complications were acceptable and excellent effects were obtained.
机译:背景:经皮射频消融(RFA)对肾细胞癌(RCC)的潜在缺陷包括:由于有限的消融区域,RFA后局部复发,由肾穿刺引起的大量出血以及难以在CT引导下穿刺观察肿瘤。目的:回顾性评估单次连续联合治疗(包括肾动脉栓塞和RFA)后不可切除RCC患者的技术成功率,有效性和并发症。资料和方法:10例不适合手术的患者(12例RCC)被包括在该初步研究中。所有肿瘤的大小范围为18-66 mm(平均31 + 3.9 mm),并在用碘化油和明胶海绵将肿瘤血管栓塞后数小时经皮消融。我们评估了该疗法的技术成功性,有效性,对肾功能的影响以及并发症。对RFA后每三个月获得的CT和/或MR图像判断有效性。根据术前,术后1周和术后3个月的肌酐水平和肾小球滤过率(GFR)评估对肾功能的影响。结果:在所有患者中,肾动脉栓塞术后经皮射频消融术均获得成功。在RFA治疗1周和3个月后获得的对比CT和/或MR图像中,我们观察到所有RCC的栓塞部分均出现坏死。手术期间和之后均无重大并发症。所有患者均报告在RFA期间可忍受的疼痛和灼热感。手术后,五名患者(50%)出现背痛,每名患者表现为积液,囊下血肿,血尿或恶心。在平均随访期47 + 3.8个月内没有复发病例。我们注意到治疗前后血清肌酐和GFR没有显着差异。结论:我们的初步研究表明,对于不能手术的RCC患者,先行先后联合肾动脉栓塞和经皮RFA联合治疗是可行的。治疗并发症可以接受,并取得了良好的效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号